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Summary
 
Four full-thickness skin wounds made in normal mice led to the significant increase in levels of
nerve growth factor (NGF) in sera and in wounded skin tissues. Since sialoadenectomy before
the wounds inhibited the rise in serum levels of NGF, the NGF may be released from the sali-
vary gland into the blood stream after the wounds. In contrast, the fact that messenger RNA
and protein of NGF were detected in newly formed epithelial cells at the edge of the wound
and fibroblasts consistent with the granulation tissue produced in the wound space, suggests
that NGF was also produced at the wounded skin site. Topical application of NGF into the
wounds accelerated the rate of wound healing in normal mice and in healing-impaired diabetic
KK/Ta mice. This clinical effect of NGF was evaluated by histological examination; the in-
creases in the degree of reepithelialization, the thickness of the granulation tissue, and the den-
sity of extracellular matrix were observed. NGF also increased the breaking strength of healing
linear wounds in normal and diabetic mice. These findings suggested that NGF immediately
and constitutively released in response to cutaneous injury may contribute to wound healing
through broader biological activities, and NGF improved the diabetic impaired response of
wound healing.
 
R
 
epair of wounds is a chain of processes necessary for
removal of damaged tissues or invaded pathogens
from the body and for complete or incomplete remodeling
of injured tissues. The healing process requires a sophisti-
cated interaction between inflammatory cells, biochemical
mediators including growth factors, extracellular matrix mole-
cules, and microenvironmental cell populations (1, 2). In-
flammatory cells, keratinocytes, and fibroblasts in the wound
space and border produce and release a variety of growth
factors such as platelet-derived growth factor (PDGF)
 
1
 
, epi-
dermal growth factor (EGF), fibroblast growth factor (FGF),
and TGF, which have biological activities to stimulate in-
filtration of inflammatory cells into the wound space, in-
duce proliferation of keratinocytes and fibroblasts, lead to
new formation of capillaries in the granulation tissue, and
modulate extracellular matrix deposition and reconstitution
of the injured area (1–5). In fact, topical application of
some growth factors is successful to accelerate healing of
full-thickness wounds in normal mice and normalize a de-
layed healing response of diabetic mice (6, 7).
Cutaneous wounds often cause anatomical and/or func-
tional damage of peripheral sensory neurons widely distrib-
uted in the skin, and nerve growth factor (NGF), which is
probably produced in the affected tissue area, may be essen-
tial to regenerate the injured neurons. Patients with diabe-
tes mellitus manifest acute and chronic complications includ-
ing cutaneous infections, immunodisturbance, and vascular
and neuropathic dysfunctions (8). Impaired production of
NGF has been reported in the submaximal gland of geneti-
cally diabetic 
 
db
 
/
 
db
 
 mice (9) and streptozotocin-induced
diabetic mice (10), and in the serum and skin of patients
with diabetes mellitus (11, 12). Although NGF is a neu-
rotrophic polypeptide mandatory for the development and
function of peripheral and central neurons (13–15), recent
findings have shown that NGF regulates immune and in-
flammatory responses through direct and/or indirect effects
on immunocompetent cells (16–22). Biologic actions of
NGF are mediated through two types of specific receptors
with distinct affinities (23, 24); the low affinity receptor is a
75-kD glycoprotein and the high affinity receptor is a 140-kD
 
1
 
Abbreviations used in this paper:
 
 bFGF, basic FGF; EGF, epidermal growth
factor; FGF, fibroblast growth factor; mRNA, messenger RNA; NGF,
nerve growth factor; PDGF, platelet-derived growth factor.
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molecules with a transmembrane tyrosine kinase domain
that is coded by the 
 
trk
 
 protooncogene (25). We have been
studying novel roles of NGF in the processes of inflamma-
tion and tissue repair. NGF caused a significant stimulation
of granulocyte differentiation from human peripheral blood
and murine bone marrow cells (26–28), suppressed apopto-
sis of rodent neutrophils and peritoneal mast cells (29, 30),
enhanced functional properties of murine neutrophils and
human eosinophils (20–22), and not only promoted colony
formation of murine IL-3–dependent bone marrow–derived
cultured mast cells, but also induced the phenotypic change
to connective tissue–type mast cells (31).
NGF is produced by many types of cells including fibro-
blasts (31, 32), keratinocytes (33), mast cells (34), and T
cells (35). Therefore, there is a possibility that NGF pro-
duced at the wounded site may regulate the healing of the
cutaneous wounds. In the present study, we demonstrated
that cutaneous wounds resulted in NGF production by the
salivary gland and regenerated keratinocytes at the edge of
the wound and fibroblasts in the granulation tissue during a
wound healing process, and that the topical application of
NGF to cutaneous wounds accelerated the rate of wound
healing in normal and diabetic mice.
 
Materials and Methods
 
Mice.
 
SJL/J mice were provided from N. Watanabe (Jikei
University School of Medicine, Tokyo, Japan). C57BL/6 and ge-
netically diabetic KK/Ta mice were purchased from Clea Japan
(Tokyo, Japan). All mice (male, 8–10 wk of age) were kept
within a filter-air laminar flow enclosure, and provided with stan-
dard laboratory food and water ad libitum. All KK/Ta mice were
diagnosed to be diabetic at the beginning of the study.
 
Cytokines and Other Reagents.
 
2.5S NGF isolated from mu-
rine submaxillary glands was a gift from A.M. Stanisz and J. Bien-
enstock (McMaster University, Hamilton, Ontario, Canada; ref-
erence 26). The preparations were purified by gel filtration on a
Sephadex G-75 column to remove traces of renin and IgG some-
times found as contaminants in the original preparation, and fur-
ther purified by affinity column chromatography with anti–
mouse NGF mAb (clone 
 
b
 
1). The affinity-purified NGF prepara-
tion was eluted as a single protein on an HPLC column (TSK
3,000; Beckman Instruments, Fullerton, CA) with a retention
time that corresponded to 27 kD (2.5S NGF dimer; reference
26). Neither EGF activity by an ELISA nor endotoxin activity by
a limulus assay was detected, even at a high concentration (10
 
m
 
g/ml) of the ultrapurified NGF preparation. Neurotrophic ac-
tivity of the ultrapurified NGF preparation was determined as
previously described (31). Recombinant murine IL-1
 
b
 
, IFN-
 
g
 
, and
TNF-
 
a
 
, and recombinant human PDGF B chain (PDGF-BB) ho-
modimer were purchased from Genzyme Corp. (Cambridge, MA).
Recombinant human basic FGF (bFGF) was purchased from Up-
state Biotechnology Inc. (Lake Placid, NY). EGF purified from
murine submaxillary glands was provided by Wako Pure Chemi-
cal Industries, Ltd. (Osaka, Japan). Recombinant human TGF-
 
b
 
1
was a gift from H. Akiyama (Kirin Brewery Company, Ltd., To-
kyo, Japan). Rabbit anti–mouse 2.5S NGF polyclonal Ab and
goat anti–rabbit IgG (H
 
1
 
L) polyclonal Ab conjugated with per-
oxidase were obtained from Sigma Chemical Co. (St. Louis, MO)
and BioMakor (Kirat Weizmann, Rehovot, Israel), respectively.
Mouse anti-2.5S NGF mAb was purchased from Boehringer
Mannheim GmbH (Mannheim, Germany). All chemicals used
were purchased from Sigma Chemical Co., unless otherwise indi-
cated.
 
Surgical Wounding.
 
Mice were wounded by using a modifica-
tion of the technique described by Denon et al. (36). Under pen-
tobarbital sodium anesthesia, hairs on the dorsum of mice were
clipped, and four full-thickness round skin wounds (5 mm diam)
were prepared using a disposable skin punch equipment (Maruho
Co., Ltd., Osaka, Japan). Each wound was separated by at least
1.5 cm of unwounded skin. A group of SJL/J mice was sialo-
adenectomized or sham operated under pentobarbital sodium an-
esthesia 4 wk before wounding. Heparinized peripheral blood
was collected from the axillary artery at 0, 1, 3, 6, and 24 h after
the skin punching. Small pieces of skin samples were removed
from the wounds and normal dorsal sites on 0, 1, 3, 7, 10, and 14 d
after the skin punching. All the blood and skin samples were ob-
tained under ether anesthesia, and were treated with protease in-
hibitors (Boehringer Mannheim GmbH) according to the manu-
facturer’s instructions. NGF levels in sera and extracts from the
skin tissues were measured by an ELISA using anti-NGF mAb
(31), which was sensitive to a lower limit of 50 pg/ml.
 
Immunohistochemical Examination.
 
Small pieces were cut from
skin tissues with wounds gently smoothed and flattened onto a
piece of thick filter, and were fixed with 4% paraformaldehyde in
0.1 M phosphate buffer (pH 7.4) for 12 h at 4
 
8
 
C. Skin tissues
were embedded in paraffin and cut at 4 
 
m
 
m; the sections were
placed on silane-coated glass slides. Tissues were deparaffinized,
rehydrated, and washed in PBS (pH 7.4). After pretreatment with
a solution of PBS supplemented with 0.3% hydrogen peroxide
and 0.1% sodium azide for 10 min to inhibit endogenous peroxi-
dase, the preparations were washed in PBS twice, and then incu-
bated with blocking medium (10% normal goat serum in PBS)
for 10 min. Rabbit anti–mouse 2.5S NGF polyclonal Ab diluted
1:2,000 in PBS supplemented with 1% BSA was applied for over-
night at 4
 
8
 
C. After washing in PBS twice, peroxidase-conjugated
goat anti–rabbit IgG (H
 
1
 
L) Ab diluted 1:100 in PBS was over-
laid for 30 min. Visualization of the reaction products was per-
formed with 0.2 mg/ml 3-3
 
9
 
 diaminobenzidine tetrahydrochlo-
ride in PBS supplemented with 0.003% hydrogen peroxide. The
tissues were counterstained with hematoxylin after the immu-
noreactions. Thin sections of submaxillary glands were provided
as a positive control.
 
In Situ Hybridization.
 
A digoxigenin-labeled antisense oligo-
nucleotide primer (5
 
9
 
-AAGGGAATGCTGAAGTTTAGTCC-
AGTGGGCTTCAGGGACAGAGTCTCC-3
 
9
 
) complementary
to nucleotides 378–425 of messenger RNA (mRNA) of mouse
NGF (37) was commercially synthesized (Nippon Flour Mills
Corp., Tokyo, Japan). Deparaffinized tissue sections were washed
in 2
 
3
 
 SSC for 10 min at 60
 
8
 
C, rinsed in 0.05M Tris-HCl (pH
7.6), and incubated in 100 
 
m
 
g/ml proteinase K (Nacalai Tesque,
Kyoto, Japan) in 0.05 M Tris-HCl (pH 7.6) for 10 min at 37
 
8
 
C.
After washing in PBS, the tissue preparations were immersed in
0.4% paraformaldehyde in PBS, pH 7.4, for 10 min at 4
 
8
 
C to ar-
rest proteolytic activity of proteinase K and rinsed in water. To
inhibit endogenous alkaline phosphatase activity, the specimens
were treated with 0.2 N hydrogen chloride for 10 min. Hybrid-
ization was performed using a slight modification of the method
reported previously (38). The specimens were hybridized with
the digoxigenin-labeled probe (20 ng/ml) in a solution of 50%
formamide, 4
 
3
 
 SSC, 0.02% Ficoll (type 400), 0.02% polyvi-
nylpyrrolidone, 0.02% BSA, 0.5 
 
m
 
g/ml salmon sperm DNA, 1%
sarcosyl (
 
N
 
-lauroyl sarcosine), 10% dextran sulfate, 0.1 M phos- 
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phate buffer (pH 7.2), and 0.05 M dithiothreitol, for 16 h at 42
 
8
 
C
in a humidified chamber. After washing, the slides were incu-
bated with alkaline phosphatase–conjugated sheep antidigoxige-
nin Ab (Boehringer Mannheim GmbH), and the reaction prod-
ucts were visualized according to the manufacturer’s instructions.
A synthesized sense oligonucleotide primer was used as a nega-
tive control. The other control experiments were performed as
follows: (
 
a
 
) RNase A treatment before hybridization, and (
 
b
 
) nei-
ther a probe nor antidigoxigenin Ab. In these experiments, little
or no positive reaction was detected.
 
Production of NGF by Fibroblasts and Keratinocytes.
 
The contact-
inhibited Swiss albino mouse embryo–derived 3T3 fibroblasts,
obtained from the Japanese Cancer Research Resources Bank (To-
kyo, Japan), and the transformed BALB/c mouse–derived kerati-
nocytes (PAM 212), provided from I. Katayama (Tokyo Medical
and Dental University School of Medicine, Tokyo, Japan), were
seeded in 35-mm culture dishes (Nunc, Roskilde, Denmark) at a
concentration of 5.0 
 
3
 
 10
 
4
 
 cells/ml in 1 ml of 
 
a
 
-MEM (GIBCO
BRL, Gaithersburg, MD) with 10% FCS (Hyclone Labs, Logan,
UT). The culture dishes that contained a confluent monolayer of
3T3 fibroblasts (0.5–1.5 
 
3
 
 10
 
6
 
 cells) on 3 d in culture were fur-
ther incubated at 37
 
8
 
C for 6 d in humidified atmosphere with 5%
CO
 
2
 
 in air after the culture medium was replaced with 1 ml of
fresh medium containing various concentrations of cytokines or
histamine. PAM 212 keratinocytes were incubated with various
concentrations of cytokines or histamine for 2 d. The culture me-
dium of both the cells was collected to measure NGF levels (see
above) and the number of fibroblasts and keratinocytes was
counted in trypsinized cultures.
 
Treatment of Wound.
 
Two different types of experiments were
conducted to evaluate a stimulating effect of NGF on wound
healing in C57BL/6 and genetically diabetic KK/Ta mice (39–
41). First, after skin punching (see above), 20 
 
m
 
l (1 
 
m
 
g) of 2.5S
NGF and vehicle solution alone (
 
a
 
-MEM with 10% FCS) were
daily applied to two left and two right wounds, respectively. Ap-
plications were carried out under pentobarbital sodium anesthesia
until the third day, and a healing term was assessed macroscopi-
cally. In other experiments, the wounds were removed 8 d after
skin punching, and were fixed in phosphate-buffered formalin.
Paraffin sections (5 
 
m
 
m thick) were made by routine methods and
stained with hematoxylin and eosin. Second, breaking strength of
healed linear wounds was examined according to a slight modifi-
cation of the methods previously reported (6). An anterior-poste-
rior linear incision (4 cm in length) in full thickness was applied
to the dorsum of mice with a scalpel under pentobarbital sodium
anesthesia. 50 
 
m
 
l (2 
 
m
 
g) of 2.5S NGF or vehicle solution alone
were administrated to the incisions, and then the wounds were
closed by wound clips placed at 1-cm intervals. Mice were killed
9 d later, and three pieces of skin (0.8 cm in width) between the
wound clips were cut vertical to the linear incision. Breaking strength
of wounds was measured by using a Rheo meter (NRM-2002J;
Fudoh Kogyo Co., Ltd, Tokyo, Japan). The ends of the skin strip
were pulled at a constant speed (20 cm/min), and breaking
strength was expressed as the mean maximum level of tensile
strength (g/mm) before separation of wounds.
 
Statistical Analysis.
 
Two-tailed Student’s 
 
t
 
 test was done for
statistical analysis of the data and 
 
P
 
 
 
,
 
0.05 was taken as the level of
significance.
 
Results
 
NGF Levels in Serum.
 
Four full-thickness round wounds
were made at the dorsal skin in SJL/J mice, and serum sam-
ples were collected under ether anesthesia at various times
after the skin punching. Although no NGF was detected in
sera isolated from anesthetized mice before the skin punch-
ing, the cutaneous wounding resulted in a rapid increase in
serum levels of NGF. Serum NGF was at a significant level
of 0.72 ng/ml at 1 h, reached a maximal level of 
 
z
 
5.20 ng/
ml at 6 h, and retained a significant level of 
 
z
 
0.88 ng/ml
even 24 h after the skin punching (Fig. 1). The serum col-
lected at 6 h after the skin punching stimulated the out-
growth of nerve fibers from rat pheochromocytoma cells
(PC12); the neurotrophic activity was completely abolished
by the addition of anti-NGF Ab (data not shown).
 
NGF Levels in Skin Tissues.
 
To examine the possible local
production of NGF at wounded sites, NGF contents at un-
wounded and wounded sites were measured on various
days after skin punching. All the cutaneous wounds were
completely closed by 11 d. Low levels of NGF were de-
tected at uninjured control skin sites isolated on various
days after wounding, ranging from 0.81 to 1.7 ng/g. In
contrast, at the wounded sites, NGF reached a maximal
level of 7.8 ng/g 1 d later, and then its levels were gradually
decreased but were higher than those at uninjured control
skin sites during the period of 14 d (Fig. 2).
 
Effect of Sialoadenectomy on NGF Levels in Sera and Wounded
Skin Sites.
 
Since the increased NGF in sera after fighting
stress has been reported to be originated from the submaxil-
lary glands (42), we conducted some experiments to examine
whether sialoadenectomy before cutaneous wounds affected
NGF levels in sera and wounded skin sites. Serum NGF
levels at 6 h in sialoadenectomized SJL/J mice were lower
than the detection limit of an ELISA, but the increased lev-
els were observed in sera of sham-operated mice as roughly
comparable to those in nonoperated normal mice (Table 1).
On the other hand, sialoadenectomy had no influence on
NGF contents at wounded skin sites 3 d after the skin
Figure 1. Serum NGF levels
in male SJL/J mice after cutane-
ous wounding. Each point rep-
resents the mean 6 SE of three
separate experiments using du-
plicate samples.
Figure 2. NGF levels at the
wounded skin site (closed) and
control unwounded skin site
(open) of male SJL/J mice after
cutaneous wounding. Each point
represents the mean 6 SE of
three separate experiments using
duplicate samples. 
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punching. Thus, we concluded that cutaneous wounds led
to rapid release of NGF from the submaxillary glands to the
peripheral blood and the subsequent local production of
NGF at the wounds.
 
Production of NGF at Wounded Skin Sites.
 
To identify cell
populations that produced NGF at wounded skin sites in
SJL/J mice 3 d after skin punching, in situ hybridization
analysis and immunohistochemical examination were pro-
vided. Granulation tissue including fibroblasts, capillaries,
and various kinds of inflammatory cells filled the wound
space under crustal tissue. Epithelium at the edge of the
wound was several cell layers thick. The leading single cell
layer edge of the epithelium was evident over the newly
formed granulation tissue, but reepithelialization was only
10–20% at this time. The stratified epithelial cells at the
wound edge showed positive staining for mRNA and pro-
tein of NGF; deeper layer epithelial cells were strongly
positive for its mRNA staining, but superficial layer epithe-
lial cells were strongly positive for its protein staining (Fig.
3, 
 
B
 
 and 
 
F
 
). In addition to the neoepithelium, fibroblasts in
granulation tissue formed in the wound space and wound
edge were positive for mRNA and protein of NGF (Fig. 3,
 
D
 
 and 
 
H
 
). In contrast, little or no reaction was observed in
epidermal keratinocytes and dermal fibroblasts at the un-
wounded control skin site. Thus, NGF was produced by
stratified epithelial cells and fibroblasts in granulation tissue
formed after wounding.
 
Effect of Various Cytokines and Histamine on NGF Produc-
tion by Fibroblasts and Keratinocytes.
 
Since NGF is produced
and released from mouse fibroblasts and keratinocytes in
vitro (31, 33), we examined the effect of inflammatory cy-
tokines (EGF, bFGF, IFN-
 
g
 
, IL-1
 
b
 
, PDGF-BB, TGF-
 
b
 
1,
and TNF-
 
a
 
) and histamine on NGF production by 3T3 fi-
broblasts and PAM 212 keratinocytes. NGF levels were as-
sessed by an ELISA in the culture medium collected from
3T3 fibroblasts on 6 d in culture and PAM 212 cells on 2 d
in culture. When 3T3 fibroblasts and PAM 212 cells were
cultured in medium alone, the collected culture medium
contained 88 
 
6
 
 3 pg/ml and 111 
 
6
 
 4 pg/ml, respectively.
The addition of EGF, bFGF, IFN-
 
g
 
, IL-1
 
b
 
, PDGF-BB,
TGF-
 
b
 
1, or histamine to 3T3 fibroblasts increased NGF
levels in the medium at the individual optimal doses by
more than three times as compared with medium alone
(Fig. 4). In contrast, the addition of TNF-
 
a
 
 at doses of 0.2–2
ng/ml resulted in slight enhancement of NGF production
(Fig. 4). When PAM 212 cells were cultured with each cy-
tokine or histamine, NGF levels were 1.5–2.5-fold higher
than those in medium alone at the individual optimal doses
of all the agents (Fig. 5). There was no significant differ-
ence in the number of fibroblasts and keratinocytes at the
end of the culture between individual groups.
 
Effect of NGF on the Rate of Wound Healing.
 
We attempted
to assess a possible positive effect of NGF on the rate of cu-
taneous wound healing in C57BL/6 control mice and ge-
netically diabetic KK/Ta mice. In C57BL/6 mice, right
full-thickness round wounds topically treated with only
medium alone for 3 d were closed by 11 d (Fig. 6). In KK/
 
Table 1.
 
NGF Levels in Sera and Wounded Skin Sites of 
Sialoadenectomized Mice
 
Sialoadenectomy
 
*
 
NGF concentrations
 
‡
 
Serum Wounded site
 
ng/ml ng/g
 
No 4.22 
 
6
 
 0.89 4.67 
 
6
 
 0.11
Yes
 
,
 
0.05 3.91 
 
6
 
 0.46
 
*SJL/J mice were sialoadenectomized or sham operated 4 wk before
skin punching.
‡Sera and skin tissues including wound were obtained 6 h and 3 d after
skin punching, respectively. Each value represents the mean 6 SE of
five separate experiments in duplicate.
Figure 3. Cellular localization of mRNA and protein of NGF in newly
formed epithelium at edge of the wound (B and F, original magnification:
240) and granulation tissue produced in the wound space (D and H, orig-
inal magnification: 550). All specimens were obtained from male SJL/J
mice 3 d after cutaneous wounding. Basal cells of the epidermis show
positive reaction for mRNA expression of NGF (B) and superficial epi-
thelial cells show positive reaction for protein of NGF (F). Positive reac-
tion for both the mRNA (D) and protein (H) of NGF is observed in fi-
broblasts in the granulation tissue. No positive reactions are observed in
the sections treated with the sense primer (A and C) and the irrelevant Ab
instead of anti-NGF Ab (E and G).301 Matsuda et al.
Ta mice, on the other hand, wound closure was delayed
.7 d compared to that in C57BL/6 mice, indicating that
the rate of wound healing was impaired in KK/Ta mice (P
,0.001), the same as genetically diabetic db/db mice (6).
When 1 mg NGF was applied to left wounds once per day
for 3 d beginning with the day of skin punching, the rate of
wound healing was significantly accelerated in both
C57BL/6 and KK/Ta mice (Fig. 6). Next, histological ex-
amination was performed on the wounds 8 d later. In
C57BL/6 mice, topical application of NGF led to the slight
accelerating effect on wound healing parameters: complete
reepithelialization, an increase in the degree of matrix den-
sity, and decreased infiltration of neutrophils (Table 2 and
Fig. 7). On the other hand, in KK/Ta mice an impairment
in wound healing was evident in incomplete reepithelial-
ization, low deposition of extracellular matrix, and contin-
uous infiltration of numerous neutrophils, but the topical
application of NGF improved the parameters of wound heal-
ing, which were comparable to those in control C57BL/6
mice without the application of NGF (Table 2 and Fig. 7).
To further evaluate the effect of NGF on wound heal-
ing, we attempted to measure breaking strength of ante-
rior–posterior incisional wounds treated with 2 mg NGF or
treated with diluent solution alone. Wound specimens were
obtained from C57BL/6 and KK/Ta mice 9 d after wound-
ing. Fig. 8 shows that breaking strength of wounds treated
with diluent solution alone in C57BL/6 was larger than
wounds in KK/Ta mice (P ,0.01). A single dose of treat-
Figure 4. Production of NGF by 3T3 fibroblasts stimulated with vari-
ous cytokines and histamine. NGF levels in culture medium were mea-
sured by a sandwich ELISA as described in Materials and Methods. Each
point represents the mean 6 SE of three separate experiments using du-
plicate samples.
Figure 5. Production of NGF by PAM 212 keratinocytes stimulated
with various cytokines and histamine. NGF levels in culture medium
were measured by a sandwich ELISA as described in Materials and Meth-
ods. Each point represents the mean 6 SE of three separate experiments
using duplicate samples.302 Nerve Growth Factor and Wound Healing
ment with NGF was sufficient to induce a significant in-
crease in breaking strength by .1.5 and 2 times in C57BL/6
and KK/Ta mice, respectively. Breaking strength of wounds
treated with NGF in KK/Ta mice was comparable to that
of wounds treated with diluent solution alone in C57BL/6
mice.
Specificity of NGF Effects on Wound Healing. To determine
the specificity of the accelerating effects of NGF on wound
healing in diabetic KK/Ta mice, NGF was pretreated in
vitro with anti-NGF Ab before the topical application to
round wounds and linear incisions. As shown in Table 3,
NGF pretreated with control Ab induced to accelerate the
rate of the wound healing parameters. On the other hand,
pretreatment with anti-NGF Ab completely abolished the
wound-healing accelerating effects of NGF. Thus, we con-
cluded that topical administration of NGF accelerated the
rate of cutaneous wound healing in control normal mice
and healing-impaired diabetic mice.
Discussion
NGF has the potential to enhance survival and functions
of immunocompetent cells, such as neutrophils, eosinophils,
mast cells, macrophages, and lymphocytes in rodents (17,
18, 20, 21, 29–31) and humans (19, 22, 43–45), suggesting
a possible ability of NGF to promote the rate of cutaneous
Figure 6. Wound healing ac-
celerated by topical applications
of NGF in control C57BL/6
mice and diabetic KK/Ta mice.
NGF (1 mg) or vehicle solution
alone was applied to the wound
space each day for 3 d beginning
with the day of wounding as de-
scribed in Materials and Meth-
ods, and a healing term was examined macroscopically. Each histogram
represents the mean 6 SE of six mice per group. *P ,0.02; ‡P ,0.01;
when compared with diluent alone.
Figure 7. Histological features of wound specimens from control C57BL/6 mice (A and B) and diabetic KK/Ta mice (C and D) 8 d after cutaneous
wounding. NGF (1 mg; B and D) or vehicle solution alone (A and C) was applied to the wound space each day for 3 d beginning with the day of wound-
ing as described in Materials and Methods. Sections were stained with hematoxylin and eosin. Original magnification: 60. Arrow heads, the original wound
margin.303 Matsuda et al.
wound healing. To clarify this point, the present study was
conducted. The full-thickness skin wounds at the dorsum
of normal mice were able to lead to the rapid increase in
levels of NGF in the peripheral blood that possessed a neu-
rotrophic ability. This response was completely abolished
by the sialoadenectomy 4 wk before the cutaneous wounds,
suggesting that biologically active NGF produced in the
submaxillary gland may be released into the peripheral blood.
This appears to be consistent with the result of Aloe et al.
(42) that showed that aggressive behavior induced the rapid
release of NGF from the salivary gland into the blood
stream through stimulation of the sympathetic nerve in
mice. Thus, biologically active NGF may be released from
the salivary gland into the blood stream in response to the
cutaneous wound as well as the fighting stress. We also
demonstrated that the cutaneous wounds resulted in the
significant increase in levels of NGF in the affected cutane-
ous tissue after the rapid release of NGF into the peripheral
blood. Liu et al. (46) reported the increased NGF levels in a
wound chamber implanted in axotomized rat sciatic nerve,
whereas serum NGF levels remained low. Since the in-
creased level of NGF was not influenced by the siaload-
enectomy, and since mRNA and protein of NGF were ob-
served in not only stratified epithelial cells at the edge of
the wound and also fibroblasts in the granulation tissue
produced in the wound space, the increased NGF in the
wounded skin may be mainly produced by newly formed
epithelial cells and fibroblasts in the granulation tissue.
A variety of inflammatory cytokines produced by local
tissues at the wound acts individually and/or collaboratively
in processes of the wound healing and tissue remodeling,
and synthesis of the cytokines also seems to be regulated
mutually. In fact, IL-1 has a potent ability to upregulate
synthesis of NGF in nonneuronal cells of injured rat sciatic
nerves (47) and in cultured rat fibroblasts (48). We at-
tempted to demonstrate whether various cytokines (EGF,
bFGF, IFN-g, IL-1b, PDGF-BB, TGF-b1, and TNF-a)
and histamine that are produced and released in injured tis-
sues (1, 3–5), affect NGF production by both 3T3 fibro-
blasts and PAM 212 keratinocytes in vitro. Interestingly, all
of the reagents except for TNF-a enhanced NGF produc-
tion of both of the cell lines. Since little or no reaction for
mRNA and protein of NGF was detected in epidermal ke-
ratinocytes and dermal fibroblasts at the uninjured control
skin site, NGF synthesis in both the cell populations acti-
vated and proliferated after the wounds seems to be regu-
lated by such cytokines released from various cell compo-
nents in local tissues including infiltrating inflammatory cells.
The local application of NGF into cutaneous wounds was
sufficient to accelerate the rate of wound healing in normal
mice and normalize the delayed healing response in dia-
betic KK/Ta mice. In addition to the results of healing rate
and breaking strength of wounds, the histological findings,
such as the increases in the degree of reepithelialization, the
thickness of the granulation tissue, and the density of extra-
cellular matrix, provided distinct evidence that NGF had a
biological ability to improve the degree of the parameters
of wound healing in normal mice and even in healing-
impaired diabetic mice. NGF also modulates proliferation
of keratinocytes in mice (49) and humans (50) through the
high affinity receptor, suggesting that NGF produced from
newly formed epithelial cells at the edge of the wound may
support reepithelialization through autocrine stimulation
mechanisms involving synergy with the other cytokines. In
Table 2. Wound Healing Accelerated by Topical Application of 
NGF in Normal C57BL/6 and Diabetic KK/Ta Mice*
Mice NGF
Reepithe-
lialization
Thickness of
granulation
tissue
Matrix
density
Acute
phase inflam-
matory cells
C57/BL/6 No 11 11 1 1
C57/BL/6 Yes 111 11 11 6
KK/Ta No 6 111 1 111
KK/Ta Yes 1 1 11 11
*NGF (1 mg) or vehicle solution alone was applied to the wound space
each day for 3 d beginning with the day of wounding, and tissue speci-
mens were removed 8 d after the wounding. The wound healing was
evaluated by histological parameters indicated. Graded as: 2, none; 6,
slight; 1, mild; 11, moderate; and 111, considerable. Data are rep-
resentative of four separate experiments.
Figure 8. Effects of NGF on
wound tear strength in control
C57BL/6 mice and diabetic KK/
Ta mice. NGF (2 mg) or vehicle
solution alone was applied to the
wound space shortly after the
wounding, and wound tear
strength was measured as de-
scribed in Materials and Meth-
ods. Each histogram represents the mean 6 SE of four mice per group.
*P ,0.01; when compared with diluent alone.
Table 3. Neutralization of the Wound Healing–accelerating Effect 
of NGF in Diabetic KK/Ta Mice by Anti-NGF Ab
Treatment*
Healing
term
Tensile
strength Factor Ab
d g/mm
None None 18.3 6 0.4‡ 10.1 6 0.8§
NGF Control Ab 15.0 6 1.2 23.2 6 2.0
NGF Anti-NGF Ab 18.5 6 0.5‡ 10.3 6 0.9§
*NGF was mixed with 10-fold diluted rabbit anti–mouse NGF Ab or
control Ab at a concentration of 50 mg/ml and incubated at 4°C for 1 h.
The NGF mixture was applied to the wound space as described in the
legends of Figs. 6 and 8, and then a healing term and wound tear
strength were measured. Each value represents the mean 6 SE of four
separate experiments.
‡P ,0.05; when compared with control Ab.
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contrast, since murine 3T3 fibroblasts have no expression
of the NGFR on their surface (21), the granulation tissue
and matrix formation induced after NGF application might
be caused by indirect promoting effects through cytokines
such as bFGF, PDGF, and TGF-b1, which contribute to
proliferation of fibroblasts and synthesis of extracellular ma-
trix by fibroblasts (51–53).
Peripheral neuropathy that occurs by complicated meta-
bolic mechanisms is one of the common complications dis-
tressing patients with diabetes mellitus; impairment of sen-
sory neurons presents as pain and loss of sensation, and
often results in cutaneous infection and impaired wound
healing (8). The recent report (13) demonstrating the de-
creased levels of endogenous NGF, a sensory neurotrophic
factor, and substance P, a sensory neurotransmitter, in the
skin of patients with diabetes mellitus, gives rise to a possi-
bility that impairment of NGF production may also con-
tribute to the pathogenesis of diabetic peripheral neuropathy.
In fact, diabetic KK/Ta mice showed impaired regenera-
tion of nerve fibers after wounding (data not shown), and
the topical administration of NGF significantly accelerated
the regeneration of nerve fibers that were roughly compa-
rable to that of control C57BL/6 mice. Apfel et al. (54)
demonstrated that exogenously administered NGF was ca-
pable of preventing the behavioral and biochemical mani-
festations of sensory neuropathy in streptozotocin-induced
diabetic rats. The present study clearly demonstrated that
the topical administration of NGF into the full-thickness
wounds by skin punching normalized the defect of diabetic
KK/Ta mice regarding the rate of wound healing. Thus,
we consider that NGF has a potentiality as a therapeutic
agent for the normalization of the diabetic impaired re-
sponse of wound healing.
We would like to thank Drs. J. Bienenstock and A.M. Stanisz (McMaster University, Hamilton, Ontario,
Canada) for providing ultrapurified NGF, Dr. I. Katayama (Tokyo Medical and Dental University, Tokyo,
Japan) for providing PAM 212 keratinocytes, and Dr. H. Akiyama (Kirin Brewery Company, Ltd., Tokyo,
Japan) for supplying TGF-b1. We also thank Dr. R. Tsuboi (Juntendo University, Tokyo, Japan) for helpful
discussions.
This work was supported by grants from the Ministry of Education, Science, Sports, and Culture, Japan, for
Recombinant Cytokine’s Project provided by the Ministry of Agriculture, Forestry, and Fisheries, Japan
(RCP 1998-4120), and from Lydia O’Leary Memorial Foundation.
Address correspondence to Hiroshi Matsuda, Department of Veterinary Clinic, Faculty of Agriculture, Tokyo
University of Agriculture and Technology, 3-5-8 Saiwai-cho, Fuchu, Tokyo 183, Japan. Phone: 81-423-67-
5784; Fax: 81-423-60-8830; E-mail: hiro@cc.tuat.ac.jp
Received for publication 12 May 1997 and in revised form 18 November 1997.
References
1. Clark, R.A.F. 1996. Wound repair: overview and general
considerations. In The Molecular and Cellular Biology of
Wound Repair. R.A.F. Clark, editor. Plenum Press, New
York. 3–50.
2. Martin, P. 1997. Wound healing–aiming for perfect skin re-
generation. Science. 276:75–81.
3. Pierce, G.F., and T.A. Mustoe. 1995. Pharmacologic en-
hancement of wound healing. Annu. Rev. Med. 46:467–481.
4. Bennett, N.T., and G.S. Schultz. 1993. Growth factors and
wound healing: biochemical properties of growth factors and
their receptors. Am. J. Surg. 165:728–737.
5. Moulin, V. 1995. Growth factors in skin wound healing. Eur.
J. Cell Biol. 68:1–7.
6. Tsuboi, R., and D.B. Rifkin. 1991. Recombinant basic fibro-
blast growth factor stimulates wound healing-impaired db/db
mice.  J. Exp. Med. 172:245–251.
7. Brown, R.E., M.P. Breeden, and D.G. Greenhalgh. 1994.
PDGF and TGF-alpha act synergistically to improve wound
healing in the genetically diabetic mouse. J. Surg. Res. 56:
562–570.
8. Siegel, J. 1995. Diabetes mellitus. In Perspectives on Patho-
physiology. L.-E.C. Copstead, editor. W.B. Saunders Com-
pany, Philadelphia. 826–845.
9. Kasayama, S., and T. Oka. 1989. Impaired production of
nerve growth factor in the submandibular gland of diabetic
mice. Am. J. Physiol. 257:E400–E404.
10. Ordonez, G., A. Fernandez, R. Perez, and J. Sotelo. 1994.
Low contents of nerve growth factor in serum and submaxil-
lary gland of diabetic mice. A possible etiological element of
diabetic neuropathy. J. Neurol. Sci. 121:163–166.
11. Faradji, V., and J. Sotelo. 1990. Low serum levels of nerve
growth factor in diabetic neuropathy. Acta Neurol. Scand. 81:
402–406.
12. Anand, P. 1996. Neurotrophins and peripheral neuropathy.
Philos. Trans. R. Soc. Lond. B Biol. Sci. 351:449–454.
13. Levi-Montalcini, R., and P.U. Angeletti. 1963. Essential role
of the nerve growth factor on the survival and maintenance
of dissociated sensory and sympathetic embryonic nerve cells
in vitro. Dev. Biol. 7:653–659.
14. Thoenen, H., and D. Edgar. 1985. Neurotrophic factors. Sci-
ence. 229:238–242.
15. Korsching, S. 1986. The role of nerve growth factor in the
CNS. Trends Neurosci. 9:570–577.
16. Gee, A.P., M.D.P. Boyle, L. Munger, M.J.P. Lawman, and
M. Young. 1983. Nerve growth factor: stimulation of poly-
morphonuclear leukocyte chemotaxis in vitro. Proc. Natl.305 Matsuda et al.
Acad. Sci. USA. 80:7215–7218.
17. Pearce, F.L., and H.L. Thompson. 1986. Some characteristics of
histamine secretion from rat peritoneal mast cells stimulated
with nerve growth factor. J. Physiol. (Lond.). 372: 379–393.
18. Thorpe, L.W., and J.R. Perez-Polo. 1987. The influence of
nerve growth factor on the in vitro proliferative response of
rat spleen lymphocytes. J. Neurosci. Res. 18:134–139.
19. Otten, U., P. Ehrhard, and R. Peck. 1989. Nerve growth
factor induces growth and differentiation of human B lym-
phocytes. Proc. Natl. Acad. Sci. USA. 86:10059–10063.
20. Kannan, Y., H. Ushio, H. Koyama, M. Okada, M. Oikawa,
T. Yoshihara, M. Kaneko, and H. Matsuda. 1991. 2.5S nerve
growth factor enhances survival, phagocytosis, and superox-
ide production of murine neutrophils. Blood. 77:1320–1325.
21. Susaki, Y., S. Shimizu, K. Katakura, N. Watanabe, K. Kawa-
moto, M. Matsumoto, M. Tsudzuki, T. Furusaka, Y. Kita-
mura, and H. Matsuda. 1996. Functional properties of mu-
rine macrophages promoted by nerve growth factor. Blood.
88:4630–4637.
22. Hamada, A., N. Watanabe, H. Ohtomo, and H. Matsuda.
1996. Nerve growth factor enhances survival and cytotoxic
activity of human eosinophils. Br. J. Haematol. 93:299–302.
23. Sutter, A., R.J. Riopelle, R.M. Harris-Warrick, and E.M.
Shooter. 1979. Nerve growth factor receptors: characteriza-
tion of two distinct classes of binding sites on chick embryo
sensory ganglia cells. J. Biol. Chem. 254:4972–4982.
24. Yanker, B.A., and E.M. Shooter. 1982. The biology and
mechanism of action of nerve growth factor. Annu. Rev. Bio-
chem. 51:845–868.
25. Kaplan, D.R., B.L. Hempstead, D. Martin-Zanca, M.V. Chao,
and L.F. Parada. 1991. The trk proto-oncogene product: a
signal transducing receptor for nerve growth factor. Science.
252:554–558.
26. Matsuda, H., M.D. Coughlin, J. Bienenstock, and J.A. Den-
burg. 1988. Nerve growth factor promotes human hemopoi-
etic colony growth and differentiation. Proc. Natl. Acad. Sci.
USA. 85:6508–6512.
27. Matsuda, H., J. Switzer, M.D. Coughlin, J. Bienenstock, and
J.A. Denburg. 1988. Human basophilic cell differentiation
promoted by 2.5S nerve growth factor. Int. Arch. Allergy Im-
munol. 86:453–457.
28. Kannan, Y., H. Matsuda, H. Ushio, K. Kawamoto, and Y.
Shimada. 1993. Murine granulocyte-macrophage and mast
cell colony formation promoted by nerve growth factor. Int.
Arch. Allergy Immunol. 132:362–367.
29. Kannan, Y., K. Usami, M. Okada, S. Shimizu, and H. Mat-
suda. 1992. Nerve growth factor suppresses apoptosis of mu-
rine neutrophils. Biochem. Biophys. Res. Commun. 186:1050–
1056.
30. Kawamoto, K., T. Okada, Y. Kannan, H. Ushio, M. Matsu-
moto, and H. Matsuda. 1995. Nerve growth factor prevents
apoptosis of rat peritoneal mast cells through the trk proto-
oncogene receptor. Blood. 86:4638–4644.
31. Matsuda, H., Y. Kannan, H. Ushio, Y. Kiso, T. Kanemoto,
H. Suzuki, and Y. Kitamura. 1991. Nerve growth factor in-
duces development of connective tissue–type mast cells in
vitro from murine bone marrow cells. J. Exp. Med. 174:7–14.
32. Young, M., J. Ofer, M.H. Blanchard, H. Asdourian, H.
Amos, and B.G.W. Arnason. 1974. Secretion of a nerve
growth factor by primary chick fibroblast cultures. Science.
187:361–362.
33. Tron, V.A., M.D. Coughlin, D.E. Jang, J. Stanisz, and D.N.
Sauder. 1990. Expression and modulation of nerve growth
factor in murine keratinocytes (PAM 212). J. Clin. Invest. 85:
1085–1089.
34. Leon, A., A. Buriani, R. dal Toso, M. Fabris, S. Romanello,
L. Aloe, and R. Levi-Montalcini. 1994. Mast cells synthesize,
store, and release nerve growth factor. Proc. Natl. Acad. Sci.
USA. 91:3739–3743.
35. Ehrhard, P.B., P. Erb, U. Graumann, and U. Otten. 1993.
Expression of nerve growth factor and nerve growth factor
receptor tyrosine kinase Trk in activated CD4-positive T-cell
clones. Proc. Natl. Acad. Sci. USA. 90:10984–10988.
36. Denon, D., M.A. Kowatch, and G.S. Roth. 1989. Produc-
tion of wound repair in old mice by local injection of mac-
rophages. Proc. Natl. Acad. Sci. USA. 86:2018–2020.
37. Scott, J., M. Selby, M. Uredea, M. Quiriga, G.I. Bell, and
W.J. Rutter. 1983. Isolation and nucleotide sequence of cDNA
encoding the precursor of mouse nerve growth factor. Na-
ture. 302:538–540.
38. Humpel, C., E. Lindqvidst, and L. Olson. 1993. Detection of
nerve growth factor mRNA in rodent salivary glands with
digoxigenin- and 32P-labeled oligonucleotides: effects of cas-
tration and sympathectomy. J. Histochem. Cytochem. 41:703–708.
39. Nakamura, M., and K. Yamada. 1967. Studies on a diabetic
(KK) strain of the mouse. Diabetologia. 3:212–221.
40. Reddi, A.S., and R.A. Camerini-Davalos. 1988. Hereditary
diabetes in the KK mouse: an overview. Adv. Exp. Med. Biol.
246:7–15.
41. Hasegawa, M., Y. Ogawa, G. Katsuura, H. Shintaku, K. Ho-
soda, and K. Nakano. 1996. Regulation of obese gene ex-
pression in KK mice and congenic lethal yellow obese KKAy
mice. Am. J. Physiol. 271:E333–E339.
42. Aloe, L., E. Alleva, A. Bohn, and R. Levi-Montalcini. 1986.
Aggressive behavior induces release of nerve growth factor
from mouse salivary gland into the bloodstream. Proc. Natl.
Acad. Sci. USA. 83:6184–6187.
43. Ehrhard, P.B., U. Ganter, J. Bauer, and U. Otten. 1993. Ex-
pression of functional trk protooncogene in human mono-
cytes. Proc. Natl. Acad. Sci. USA. 90:5423–5427.
44. Bischoff, S., and C.A. Dahinden. 1992. Effect of nerve
growth factor on the release of inflammatory mediators by
mature human basophils. Blood. 792:2662–2669.
45. Torcia, M., L. Bracci-Laudiero, M. Lusibello, L. Nencioni,
D. Labardi, A. Rubartelli, F. Cozzolino, L. Aloe, and E. Ga-
raci. 1996. Nerve growth factor is an autocrine survival factor
for memory B lymphocytes. Cell. 85:345–356.
46. Liu, H.M., H.Y. Lei, and K.P. Kao. 1995. Correlation be-
tween NGF levels in wound chamber fluid and cytological
location of NGF and NGF receptor in axotomized rat sciatic
nerve. Exp. Neurol. 132:24–32.
47. Lindholm, D., R. Heumann, M. Meyer, and H. Thoenen.
1987. Interleukin-1 regulates synthesis of nerve growth factor
in non-neuronal cells of rat sciatic nerve. Nature. 330:658–659.
48. Lindholm, D., R. Heumann, B. Hengerer, and H. Thoenen.
1988. Interleukin 1 increases stability and transcription of
mRNA encoding nerve growth factor in cultured rat fibro-
blasts. J. Biol. Chem. 263:16348–16351.
49. Paus, R., M. Luftle, and B.M. Czarnetzki. 1994. Nerve
growth factor modulates keratinocyte proliferation in murine
skin organ culture. Br. J. Dermatol. 130:174–180.
50. Di Marco, E., M. Mathor, S. Bondanza, N. Cutuli, P.C.
Marchisio, R. Cancedda, and M. De Luca. 1993. Nerve growth
factor binds to normal human keratinocytes through high and
low affinity receptors and stimulates their growth by a novel
autocrine loop. J. Biol. Chem. 268:22838–22846.306 Nerve Growth Factor and Wound Healing
51. Buckley-Sturrock, A., S.C. Woodward, R.M. Senior, G.L.
Griffin, M. Klagsbrun, and J.M. Davidson. 1989. Differential
stimulation of collagenase and chemotactic activity in fibro-
blasts derived from rat wound repair tissue and human skin
by growth factors. J. Cell. Physiol. 138:70–78.
52. Pierce, G.F., T.A. Mustoe, B.W. Altrock, T.F. Deuel, and A.
Thomason. 1991. Role of platelet-derived growth factor in
wound healing. J. Cell. Biochem. 45:319–326.
53. Roberts, A.B., M.B. Sporn, R.K. Assoian, J.M. Smith, N.S.
Roche, L.M. Wakefield, U.I. Heine, L.A. Liotta, V. Flalnga,
J.H. Kehrl, and A.S. Fauci. 1986. Transforming growth fac-
tor type B: rapid induction of fibrosis and angiogenesis in vivo
and stimulation of collagen formation in vitro. Proc. Natl.
Acad. Sci. USA. 83:4167–4171.
54. Apfel, S.C., J.C. Arezzo, M. Brownlee, H. Federoff, and J.A.
Kessler. 1994. Nerve growth factor administration protects
against experimental diabetic sensory neuropathy. Brain Res.
634:7–12.